Shayana Pharm

Shayana Pharm is an Israeli biotechnology company focused on the development of stable, synthetic cannabinoid acid derivatives for medical use. The company was co-founded by the late Professor Raphael Mechoulam, a pioneer in cannabinoid research, to harness the therapeutic potential of cannabinoid acids which are typically unstable in their natural form. Their proprietary platform creates synthetic versions of molecules like cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) that maintain high potency and stability while remaining non-psychoactive. The lead candidate, EPM301, is a synthetic CBDA derivative being investigated for its anti-inflammatory and anti-anxiety properties. Shayana Pharm targets a range of indications including psoriasis, inflammatory bowel disease, and various neuropsychiatric disorders. By providing consistent and scalable synthetic alternatives to plant-derived compounds, the company aims to bridge the gap between traditional herbal medicine and modern pharmaceutical standards.